



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12P 21/04, C12N 1/20, 9/00, 9/12, 9/14, 15/00, C07K 1/00, A61K 38/24, 38/26, 38/28, 38/31		A1	(11) International Publication Number: WO 98/30715 (43) International Publication Date: 16 July 1998 (16.07.98)
(21) International Application Number: PCT/US97/19453 (22) International Filing Date: 24 October 1997 (24.10.97) (30) Priority Data: 60/035,770 7 January 1997 (07.01.97) US 60/059,792 23 September 1997 (23.09.97) US (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Applications US 60/035,770 (CIP) Filed on 7 January 1997 (07.01.97) US 60/059,792 (CIP) Filed on 23 September 1997 (23.09.97) (71) Applicants (for all designated States except US): CALIFORNIA INSTITUTE OF TECHNOLOGY [US/US]; 1201 East California Boulevard, Pasadena, CA 91125 (US). THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US/US]; 22nd floor, 300 Lakeside Drive, Oakland, CA 94612-3550 (US).		(72) Inventors; and (75) Inventors/Applicants (for US only): SIEGAL, Micah, S. [US/US]; 2255 Hearst Avenue #18, Berkeley, CA 94709 (US). ISACOFF, Ehud, Y. [US/US]; 5454 Boyd Avenue, Oakland, CA 94618 (US). (74) Agent: HARRIS, Scott, C.; Fish & Richardson P.C., Suite 1400, 4225 Executive Square, La Jolla, CA 92037 (US). (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published With international search report.	
(54) Title: OPTICAL SENSORS OF CELL SIGNALING			
(57) Abstract			
<p>A chimeric protein sensor including an optically active polypeptide linked to a responsive polypeptide, or responsive fragment thereof, which undergoes a change in response to a cell signaling event, wherein an optical property of the sensor is altered in response to the change in the responsive polypeptide, or responsive fragment thereof is provided, as well as nucleic acid sequences encoding the chimeric protein sensor. The chimeric protein sensor includes an optically active polypeptide or fragment thereof, such as green fluorescent protein (GFP), for measuring cellular events <i>in vivo</i>.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NI	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

OPTICAL SENSORS OF CELL SIGNALING

Background of the Invention

This invention relates generally to the field of cellular signaling, and more
5 specifically to methods for measuring changes that occur during a cell signaling event
using optical sensors having fluorescent properties.

Field of the Invention

Fluorescent indicator dyes revolutionized the understanding of cellular
physiology by providing a means for continuous measurements in single cells and cell
10 populations. Presently, these dyes are synthesized chemically and introduced as
hydrolyzable esters or by microinjection (Cohen, L., and Leshner, S. (1986) Soc. Genl.
Physiologists, 40:71-99; Gross, D., and Loew, L.M. (1989) Methods in Cell Biology,
30:193-218; Tsien, R.Y. (1989) Ann. Rev. Neuroscience, 12:227-253). Delivering
indicator dyes to specific cell populations has proven to be a difficult problem. In the
15 absence of such cell-specific localization, optical measurement in a tissue cannot
distinguish the particular cell population that initiates a signal.

Fluorescent proteins have been used as markers of gene expression, tracers
of cell lineage, and fusion tags to monitor protein location within cells (*e.g.*, Chalfie,
M., *et al.*, Science 263:802-5). Green fluorescent protein (GFP), a small protein,
20 consisting of only 238 amino acids, has been cloned from *Aequorea victoria* (Prasher,
D.C., *et al.* (1992) Gene, 111:229-233). The chromophore of GFP is generated
autocatalytically (Heim, R., *et al.* (1994) Proc. Nat'l. Acad. Sci. USA, 91: 12501-
12504), and the protein is stable and functional in many cell types. The crystal
structure of GFP has been solved by X-ray diffraction (Ormo, M., *et al.* (1996)
25 Science, 273:1392-1395; Yang, F., *et al.* (1996) Nat. Biotechnol., 14:1246-1251).
Mutant versions of the green fluorescent protein have been identified that exhibit
altered fluorescence characteristics, including different excitation and emission

- 2

maxima. Fluorescent molecules are attractive as sensors because of the ease of quantification and the highly sensitive nature of the assays. Fluorescent proteins can be produced *in vivo* by biological systems, and can be used to trace intracellular
5 events. GFP has been shown to fluoresce when expressed from the cDNA, indicating that the protein can undergo the cyclization and oxidation necessary for fluorescence *in vivo*.

Despite the tremendous advances in the field of genetic engineering and expression of a DNA of interest in a desired cell, few tools exist in the art for the
10 direct, selective measurement of a specific physiological response in a cell. For example, although cell growth can be stimulated during *in vitro* culture by inclusion of growth factors in the culture medium, there are few adequate means available to directly measure changes in cellular events in response to growth factor administration.

15

Summary of the Invention

This invention provides optical sensors for measuring cell signaling or cellular events *in vitro* or *in vivo*. The sensors of the invention are chimeric proteins including an optically active polypeptide or fragment thereof, operatively linked to a responsive polypeptide, or responsive fragment thereof. The chimeric protein
20 typically exists in a particular state prior to a cellular event, which state measurably changes during or following the event. Depending on the conformational shape or the state assumed by the expressed protein, a property of the optically active polypeptide changes (*e.g.*, a fluorescence characteristic), thereby making it possible to differentiate between an event before and after it has occurred, and thus an activity of
25 the cell, via the optical output.

In one embodiment, the invention features nucleic acid sequences which encode a chimeric protein including an optically active polypeptide linked to a responsive polypeptide, or responsive fragment thereof, which undergoes a change in response to a cell signaling event and

- 3

wherein an optical property of the sensor is altered in response to the change. Preferably, the optically active polypeptide or fragment thereof is a fluorescent protein such as GFP.

5 In another embodiment, the invention features a method for determining the presence of an activity in a sample including contacting the sample with a chimeric protein of the invention; exciting the chimeric protein; and measuring the amount of an optical property in the presence and absence of activity, such that a change in the optical property is indicative of activity. The invention also features a
10 method for determining if a cell exhibits an activity, which includes transfecting a cell with a nucleic acid encoding a chimeric protein of the invention; exciting the chimeric protein; and measuring the amount of an optical property in the presence of the activity and in the absence of the activity, such that a change in the optical property is indicative of activity.

15 The invention also includes a method for determining whether a compound alters a cell signaling event, including contacting a sample containing a known amount of a cell signaling activity with a test compound and a chimeric protein of the invention; exciting the chimeric protein; measuring the amount of cell signaling activity in the sample as a function of the quantity of change or rate of
20 change of an optical property that differs before and after the cell signaling event; and comparing the amount of activity in the sample with a standard activity for the same amount of the cell signaling event, whereby a difference between the amount of activity in the sample and the standard activity indicates that the compound alters a cell signaling event.

25 In yet another embodiment, the invention provides a kit for determining the presence of an activity in a sample, including either a chimeric protein of the invention, or a nucleic acid sequence encoding a chimeric protein of the invention. The kit including a nucleic acid encoding a chimeric sensor protein of the invention may provide a host cell stably transfected with the nucleic acid sequence, wherein the
30 cell is now an optical indicator. Thus, the invention also provides a recombinant cell line containing the chimeric protein of the invention. In a specific example provided

- 4

herein, the responsive polypeptide is a voltage-gated ion channel and the optically active polypeptide is GFP, more specifically, a deletion mutant of GFP. Other modified GFPs are useful in the invention.

- 5 Another embodiment of the invention provides a non-human transgenic animal, such as a mouse, which has incorporated into its genome a recombinant nucleic acid sequence encoding a chimeric protein of the invention.

Brief Description of the Drawings

Fig. 1A is a diagram of the FlaSh construct, consisting of a green
10 fluorescent protein gene inserted in-frame into the Shaker K⁺ channel.

Fig. 1B is the putative orientation of the FlaSH protein in the cell membrane.

Fig. 1C shows *Xenopus* oocytes 14 days after injection with cRNA encoding FlaSh.

- 15 Fig. 2A is the simultaneous two-electrode voltage clamp recording and photometry indicating fluorescence changes in response to voltage steps (v) between -60mV and +10mV, in 10mV increments.

Fig. 2B is the correlation of FlaSh fluorescence with Shaker action gating.

- Fig. 2C illustrates the independence of the kinetics of fluorescence change
20 of FlaSh from voltage at extreme potentials.

Fig. 3 shows that brief depolarizations of cells expressing FlaSh evoke stereotypical fluorescence responses.

Fig. 4 demonstrates that FlaSh response to brief pulses can be detected in single sweeps.

Description of the Preferred Embodiments

5 Chimeric Proteins

The sensors of the invention are chimeric proteins having an optically active polypeptide in operative linkage with a responsive polypeptide, or responsive fragment thereof. The chimeric protein or responsive polypeptide normally exists in one state *e.g.*, conformational shape or charge, prior to a cellular event or cell
10 signaling event, and undergoes a change during or after a cell signaling event. Depending on the state assumed by the chimeric polypeptide, an optical property of the sensor will change, thereby making it possible to differentiate between states of the polypeptide, and thus the activity of the cell, via the optical output. An advantage of the invention is that the sensitivity and range of operation of sensors of the
15 invention are determined by the responsive polypeptide or the chimeric polypeptide, thus the sensors are able to detect biologically relevant signals. Calibration of the sensors also allows translation of the optical parameter (*e.g.*, units of fluorescence) into units of activity.

"A cell signaling event", "cellular event" or "cell signaling" as used
20 herein refers to the generation of a biochemical or physiological response as a result of an event occurring during cellular metabolism, regulation, growth, differentiation, stimulation, division, or death. In general, cell signaling events result in a change of a molecular characteristic of the cell as compared to the characteristic prior to the event.

25 A "chimeric" polypeptide as used herein refers to a polypeptide containing all or a fragment of amino acid sequence derived from one protein connected, linked or fused with all or a fragment of amino acid sequence derived from at least one other protein. The amino acid sequences can be linked contiguously, or end to end, as in a

- 6

standard fusion protein, or can be rearranged within each other, so long as the biological or functional activities of each protein or fragment thereof are retained.

For example, the chimeric protein of the invention contains at least one polypeptide of
5 fragment thereof which is the "responsive" polypeptide and one which is the
"optically active" polypeptide. In an illustrative example provided herein, a Shaker
channel polypeptide is fused in operative linkage with a truncated GFP (deletion
mutation at amino acid residues 233-238). Given the teachings herein and the
knowledge of those of skill in the art, it would not require undue experimentation to
10 construct other chimeric or fusion proteins useful as optical sensors as described in
the present invention.

"Operative linkage" between the responsive polypeptide and the optically
active polypeptide refers to a juxtaposition wherein the components so
described are in a relationship permitting them to function in their intended manner.

15 A responsive polypeptide operatively linked to an optically active polypeptide is
connected such that the optically active polypeptide is responsive to a "change" in the
responsive polypeptide in response to a cellular or cell signaling event.

The "responsive polypeptide" is any polypeptide that may undergo a
change in a state of the polypeptide during a cell signaling event. The responsive
20 polypeptide may be "responsive" prior to or following construction of a chimeric
polypeptide of the invention. In other words, the operative linkage with an optically
active polypeptide may provide responsiveness to the polypeptide. Such changes or
states include conformational changes, change in charge, and change in
phosphorylation or methylation status, dimerization status, protein/protein or
25 protein/nucleic acid interaction, for example.

As used in connection with the present invention, the term "polypeptide"
refers to a polymer in which the monomers are amino acid residues which are joined
together through amide bonds. When the amino acids are alpha-amino acids, either
the L-optical isomer or the D-optical isomer can be used, the L-isomers being
30 preferred. The terms "polypeptide" as used herein is intended to encompass any
amino acid sequence and include modified sequences such as glycoproteins. The term

- 7

“polypeptide” is specifically intended to cover naturally occurring proteins, as well as those which are recombinantly or synthetically synthesized, which occur in at least two different conformations wherein both conformations have the same or
5 substantially the same amino acid sequence but have different three dimensional structures.

“Conformation” is the three-dimensional arrangement of side groups in a molecule; a change in conformation occurs when the three-dimensional structure of a molecule changes. Examples of conformational changes include a shift from α -helix
10 to a β -sheet or a shift from β -sheet to a α -helix.

“Fragments” as used herein are a portion of a naturally occurring protein which can exist in at least two different states or conformations. Fragments can have the same or substantially the same amino acid sequence as the naturally occurring protein. “Substantially the same” means that an amino acid sequence is largely, but
15 not entirely, the same, but retains a functional activity of the sequence to which it is related. In general two amino acid sequences are substantially the same” or “substantially homologous” if they are at least 85% identical. Fragments which have different three dimensional structures as the naturally occurring protein are also included. The term “responsive” as used herein is intended to encompass any change
20 in a polypeptide that occurs following a particular cell signaling event, which is directly or indirectly caused by that cell signaling event (e.g., conformational change in a voltage-gated ion channel (e.g., Shaker) in detection of membrane voltage across the cell; phosphorylation of a hormone receptor resulting in a conformational change in the receptor upon hormone stimulation).

25 Classes of responsive polypeptides the invention include, but are not limited to, channel proteins, receptors, enzymes, and G-proteins. Channel polypeptides useful with the invention include, but are not limited to voltage-gated ion channels including the potassium, sodium, chloride, G-protein-responsive, and calcium channels. A “channel polypeptide” is a polypeptide embedded in the cell
30 membrane which is part of a structure that determines what particle sizes and or charges are allowed to diffuse into the cell. Channel polypeptides include the

“voltage-gated ion channels”, which are proteins imbedded in a cell membrane that serve as a crossing point for the regulated transfer of a specific ion or group of ions across the membrane. Several ion channel polypeptides of use with the invention are
 5 listed in Table I.

Table I. Ion Channels

Gene Product	Genbank Accession No.
Human voltage-gated chloride ion channel CLCN5	X91906
Human delayed rectifier potassium channel (Isk) gene	L33815
10 Human potassium channel protein (HPCN3) gene	M55515
Human potassium channel (HPCN2) (mRNA)	M55514
Human potassium channel (HPCN1) (mRNA)	M55513
Human gamma subunit of epithelial amiloride-sensitive sodium channel (mRNA)	X87160
15 Human beta subunit of epithelial amiloride-sensitive sodium channel	X87159

Channels also include those activated by intracellular signals such as those where the signal is by binding of ligand such as calcium, cyclic nucleotides, G-proteins, phosphoinositols, arachidonic acid, for example, and those where the signal
 20 is by a covalent modification such as phosphorylation, enzymatic cleavage, oxidation/reduction, and acetylation, for example. Channel proteins also include those activated by extracellular ligands (e.g., ionotropic receptors). These can be activated by acetylcholine, biogenic amines, amino acids, and ATP, for example.

A “receptor polypeptide” is a polypeptide found on a cell, often on a
 25 membrane, that can combine with a specific type of molecule, *e.g.*, a ligand, which alters a function of the cell. Receptor polypeptides of use with the invention include,

- 9

but are not limited to, the growth factor receptors, hormone receptors, cytokine receptors, neurotransmitter receptors, ligand-gated channels, and steroid receptors. Specifically polypeptides encoding insulin-like growth factor, insulin, somatostatin, glucagon, interleukins, e.g., IL-2, transforming growth factors (TGF- α , TGF- β), platelet-derived growth factor (PDGF), epidermal growth factor (EGF), nerve growth factor (NGF), fibroblast growth factor (FGF), interferon- γ (IFN- γ), and GM-CSF receptors are of use with the invention. Receptors are "metabotropic", such as those where binding of ligand is transmitted to a G-protein (e.g., for 7-transmembrane receptors) or kinase domains (for single transmembrane receptors). These can be activated by acetylcholine, biogenic amines, amino acids, ATP, and many peptides, such as opioids, hypothalamic-releasing hormones, neurohypophyseal hormones, pituitary hormones, tachykinins, secretins, insulins, somatostatins, and gastrointestinal peptides. Several receptor polypeptides of use with the invention are listed in Table II.

Table II. Receptors

Gene Product	Genbank Accession No.
Human insulin receptor gene	M29929
Human somatostatin receptor gene	L14856
Human IL-2 receptor gene	X01057, X01058, XD1402
Human TGF receptor (mRNA)	M8509
Human PDGF receptor (mRNA)	M22734
Human EGF receptor gene	X06370
Human NGF receptor (mRNA)	M14764
Human FGF receptor (mRNA)	M34641
Human GM-CSF receptor (mRNA)	M73832
Human IFN- γ receptro (mRNA)	X62468

An "enzyme" is a polypeptide that acts as a catalyst, which speeds the rate at which biochemical reactions proceed do not alter the direction or nature of the reaction. Enzyme polypeptides useful in the invention include, but are not limited to, protein kinases, catalyses, amidase, phosphatases, guanylyl and adenylyl cyclases, and lipoxygenases. Polypeptides encoding the serine/threonine protein kinases are of use with the invention. Several genes encoding human enzymes of use with the invention are listed in Table III.

Table III. Enzymes

Gene Product	Genbank Accession No.
Human cAMP dependent protein kinase AKAD 79 (mRNA)	M90359
5 Human protein kinase C beta gene	D10022
Human lipid-activate protein kinase PRK-1 (mRNA)	U33053
Human guanine nucleotide binding protein alpha subunit gene	M21142, J03647, M21139
Human serine/threonine kinase (mRNA)	M83780

The change in conformation or state that occurs in the responsive peptide

10 during cell signaling or cellular events results in a change in an optical characteristic of the sensor. The change can be the result of an alteration in the environment, structure, or oligomerization status of the sensor. The molecular component responsible for a conformational change is known for many enzymes (e.g., Blostien, R., *et al.* (1997) *J. Biol. Chem.*, 272:24987-93; Shoelstein, Se.E., *et al.*, (1993) *EMBO*

15 *J.*, 12:795-802), receptors (e.g. Moyle, W.R., *et al.*, (1995) *J. Biol. Chem.*, 270:20020-20031; Baron, V., *et al.*, (1992), *J. Biol. Chem.* 267:23290-23294), and channels (e.g., Bouzat. A., *et al.*, (1994) *Neuron*, 13: 1395-1402; Dulhanty, A.M., (1994) *Biochemistry*, 33:4072-79). The optical properties of the sensor which can be altered in response to the conformational change in the responsive polypeptide include, but

20 are not limited to, changes in the excitation or emission spectrum, quantum yield, extinction coefficient, excited life-time and degree of self-quenching for example. The cause of the changes in these parameters may include but are not limited to changes in the environment, changes in the rotational or vibrational freedom of the sensor, changes in the angle of the sensor with respect to the exciting light or the

25 optical detector apparatus, or changes in distance or dipole orientation between

sensors on associated responsive polypeptides.

In the chimeric proteins of the invention, the responsive polypeptide is operably linked to an optically active polypeptide. A protein-based "optically active
5 polypeptide" is a polypeptide which contains a means for emitting light.

Fluorescence is one optical property of an optically active polypeptide which can be used as the means of detecting a conformational change of the responsive polypeptide of the chimeric proteins of the invention. As used herein, the term "fluorescent property" refers to the molar extinction coefficient at an appropriate excitation
10 wavelength, the fluorescence quantum efficiency, the shape of the excitation spectrum or emission spectrum, the excitation wavelength maximum and emission wavelength maximum, the ratio of excitation amplitudes at two different wavelengths, the ratio of emission amplitudes at two different wavelengths, the excited state lifetime, or the fluorescence anisotropy. A measurable difference in any one of these properties
15 between the active and inactive states suffices for the utility of the fluorescent protein substrates of the invention in assays for activity. A measurable difference can be determined by determining the amount of any quantitative fluorescent property, *e.g.*, the amount of fluorescence at a particular wavelength, or the integral of fluorescence over the emission spectrum. Optimally, the protein substrates are selected to have
20 fluorescent properties that are easily distinguishable in the un-activated and activated conformational states.

One means of measuring fluorescence in a sample uses a fluorimeter. In general, excitation radiation, from an excitation source having a first wavelength, passes through excitation optics. The excitation optics cause the excitation radiation
25 to excite the sample. In response, fluorescent proteins in the sample emit radiation which has a wavelength that is different from the excitation wavelength. Collection optics then collect the emission from the sample. The device can include a temperature controller to maintain the sample at a specific temperature while it is being scanned. According to one embodiment, a multi-axis translation stage moves a
30 microtiter plate holding a plurality of samples in order to position different wells to be exposed. The multi-axis translation stage, temperature controller, auto-focusing

- 13

feature, and electronics associated with imaging and data collection can be managed by an appropriately programmed digital computer. The computer also can transform the data collected during the assay into another format for presentation. Other means
5 of measuring fluorescence can also be used with the invention.

Methods of performing assays on fluorescent materials are well known in the art and are described in, *e.g.*, Lakowicz, J.R., *Principles of Fluorescence Spectroscopy*, New York: Plenum Press (1983); Herman, B., Resonance energy transfer microscopy, in: *Fluorescence Microscopy of Living Cells in Culture, Part B*,
10 *Methods in Cell Biology*, vol. 30, ed. Taylor, D.L. & Wang, Y.-L., San Diego: Academic Press (1989), pp. 219-243; Turro, N.J., *Modern Molecular Photochemistry*, Menlo Park: Benjamin/Cummings Publishing Co., Inc. (1978), pp. 296-361.

Any fluorescent protein can be used in the invention, including proteins that fluoresce due to intramolecular rearrangements or the addition of cofactors that
15 promote fluorescence. For example, green fluorescent proteins of cnidarians, which act as their energy-transfer acceptors in bioluminescence, are suitable fluorescent proteins for use in the fluorescent indicators. A green fluorescent protein ("GFP") is a protein that emits green light, and a blue fluorescent protein ("BFP") is a protein that emits blue light. GFPs have been isolated from the Pacific Northwest jellyfish,
20 *Aequorea victoria*, the sea pansy, *Renilla reniformis*, and *Phialidium gregarium*. See, Ward, W.W., *et al.*, *Photochem. Photobiol.*, 35:803-808 (1982); and Levine, L.D., *et al.*, *Comp. Biochem. Physiol.*, 72B:77-85 (1982).

A variety of *Aequorea*-related GFPs having useful excitation and emission spectra have been engineered by modifying the amino acid sequence of a naturally
25 occurring GFP from *Aequorea victoria*. (See, Prasher, D.C., *et al.*, *Gene*, 111:229-233 (1992); Heim, R., *et al.*, *Proc. Natl. Acad. Sci., USA*, 91:12501-04 (1994); U.S. Patent No. 5,491,084; 5,625,048). The cDNA of GFP can be concatenated with those encoding many other proteins; the resulting chimerics often are fluorescent and retain the biochemical features of the partner proteins. (See,
30 Cubitt, A.B., *et al.*, *Trends Biochem. Sci.* 20:448-455 (1995)). Mutagenesis studies have produced many GFP mutants, some having shifted wavelengths of excitation or

- 14

emission. Such proteins are included in the invention sensor. A fluorescent protein is an "*Aequorea*-related fluorescent protein" if any contiguous sequence of 150 amino acids of the fluorescent protein has at least 85% sequence identity with an amino acid sequence, either contiguous or non-contiguous, from the wild type *Aequorea* green fluorescent protein. More preferably, a fluorescent protein is an *Aequorea*-related fluorescent protein if any contiguous sequence of 200 amino acids of the fluorescent protein has at least 95% sequence identity with an amino acid sequence, either contiguous or non-contiguous, from the wild type *Aequorea* green fluorescent protein. Similarly, the fluorescent protein can be related to *Renilla* or *Phialidium* wild-type fluorescent proteins using the same standards.

The fluorescent indicators can be produced as chimeric proteins by recombinant DNA technology. Recombinant production of fluorescent proteins involves expressing nucleic acids having sequences that encode the proteins. Nucleic acids encoding fluorescent proteins can be obtained by methods known in the art. For example, a nucleic acid encoding the protein can be isolated by polymerase chain reaction of cDNA from *A. victoria* using primers based on the DNA sequence of *A. victoria* green fluorescent protein. PCR methods are described in, for example, U.S. Pat. No. 4,683,195; Mullis, *et al.* *Cold Spring Harbor Symp. Quant. Biol.* 51:263 (1987), and Erlich, ed., *PCR Technology*, (Stockton Press, NY, 1989). Mutant versions of fluorescent proteins can be made by site-specific mutagenesis of other nucleic acids encoding fluorescent proteins, or by random mutagenesis caused by increasing the error rate of PCR of the original polynucleotide with 0.1 mM MnCl₂ and unbalanced nucleotide concentrations.

In a particular embodiment of the present invention, a C-terminal truncated GFP (GFP Δ 233-238; numbers refer to amino acid residues) is utilized in the chimeric protein (see Examples). This C-terminal deletion mutant was fused in-frame into the Shaker-ion channel into a region just after the sixth putative transmembrane helix (at the SpeI site). Thus, in another embodiment of the invention is provided a new GFP as an optically active polypeptide or optically active fragment of wild-type GFP. Other GFPs having C-terminal mutations are included in the invention.

- 15

In the chimeric proteins of the invention, the responsive polypeptide is operably linked to an optically active polypeptide, which changes conformation in response to a cell signaling event. Cell signaling events that occur *in vivo* can be of very short duration. The optically active polypeptides of the invention allow measurement of the optical parameter, such as fluorescence, which is altered in response to the cell signal, over the same time period that the event actually occurs. Alternatively, the response can be measured after the event occurs (over a longer time period) as the conformational change that occurs in an optically active polypeptide can be of a longer duration than the cell signaling event itself.

Nucleic Acid Constructs of the Invention

In another embodiment, the invention provides isolated nucleic acid sequences which encode an optically active polypeptide operatively linked to a responsive polypeptide, or fragment thereof, which normally exists in one state *e.g.*, conformational shape or charge, prior to a cellular event or cell signaling event, and undergoes a change during or after a cell signaling event.

“Polynucleotide” or “nucleic acid sequence” refers to a polymeric form of nucleotides at least 10 bases in length. By “isolated nucleic acid sequence” is meant a polynucleotide that is not immediately contiguous with both of the coding sequence with which it is immediately contiguous (one on the 5' end and one on the 3' end) in the naturally occurring genome of the organism from which it is derived. The term therefore includes, for example, a recombinant DNA which is incorporated into a vector; into an autonomously replicating plasmid or virus; or into the genomic DNA of a prokaryotic or eukaryotic cell or organism, or which exists as a separate molecule (*e.g.* a cDNA) independent of other sequences. The nucleotides of the invention can be ribonucleotides, deoxyribonucleotides, or modified forms of either nucleotide. The term includes single and double stranded forms of DNA.

Nucleic acid sequences which encode an optically active polypeptide operatively linked to a responsive polypeptide, or fragment thereof, which normally has two or more states or conformational arrangements, and which undergoes a

- 16

change during a cell signaling event can be operatively linked to expression control sequences. "Operatively linked" refers to a juxtaposition wherein the components so described are in a relationship permitting them to function in their intended manner.

- 5 An expression control sequence operatively linked to a coding sequence is ligated such that expression of the coding sequence is achieved under conditions compatible with the expression control sequences. As used herein, the term "expression control sequences" refers to nucleic acid sequences that regulate the expression of a nucleic acid sequence to which it is operatively linked. Expression control sequences are
- 10 operatively linked to a nucleic acid sequence when the expression control sequences control and regulate the transcription and, as appropriate, translation of the nucleic acid sequence. Thus, expression control sequences can include appropriate promoters, enhancers, transcription terminators, a start codon (*i.e.*, ATG) in front of a protein-encoding gene, splicing signals for introns, maintenance of the correct reading
- 15 frame of that gene to permit proper translation of the mRNA, and stop codons. The term "control sequences" is intended to include, at a minimum, components whose presence can influence expression, and can also include additional components whose presence is advantageous, for example, leader sequences and chimeric partner sequences. Expression control sequences can include a promoter.

- 20 By "promoter" is meant minimal sequence sufficient to direct transcription. Also included in the invention are those promoter elements which are sufficient to render promoter-dependent gene expression controllable for cell-type specific, tissue-specific, or inducible by external signals or agents; such elements may be located in the 5' or 3' regions of the gene. Both constitutive and inducible
- 25 promoters, are included in the invention (see *e.g.*, Bitter *et al.*, 1987, Methods in Enzymology 153:516-544). For example, when cloning in bacterial systems, inducible promoters such as pL of bacteriophage γ , plac, ptrp, ptac (ptrp-lac hybrid promoter) and the like may be used. When cloning in mammalian cell systems, promoters derived from the genome of mammalian cells (*e.g.*, metallothionein
- 30 promoter) or from mammalian viruses (*e.g.*, the retrovirus long terminal repeat; the adenovirus late promoter; the vaccinia virus 7.5K promoter; CMV promoter) may be

- 17

used. Promoters produced by recombinant DNA or synthetic techniques may also be used to provide for transcription of the nucleic acid sequences of the invention.

5 In the present invention, the nucleic acid sequences encoding the chimeric protein of the invention may be inserted into a recombinant expression vector. The term "recombinant expression vector" refers to a plasmid, virus or other vehicle known in the art that has been manipulated by insertion or incorporation of the nucleic acid sequences encoding the chimeric peptides of the invention. The
10 expression vector typically contains an origin of replication, a promoter, as well as specific genes which allow phenotypic selection of the transformed cells. Vectors suitable for use in the present invention include, but are not limited to the T7-based expression vector for expression in bacteria (Rosenberg, *et al.*, *Gene*, 56:125, 1987), the pMSXND expression vector, or adeno or vaccinia viral vectors for expression in
15 mammalian cells (Lee and Nathans, *J. Biol. Chem.*, 263:3521, 1988), baculovirus-derived vectors for expression in insect cells, cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV.

 The nucleic acid sequences encoding an optically active polypeptide of the invention can also include a localization sequence to direct the indicator to particular
20 cellular sites by fusion to appropriate organellar targeting signals or localized host proteins. A polynucleotide encoding a localization sequence, or signal sequence, can be ligated or fused at the 5' terminus of a polynucleotide encoding the fluorescence indicator such that the signal peptide is located at the amino terminal end of the resulting chimeric polynucleotide/polypeptide. In the case of eukaryotes, the signal
25 peptide is believed to function to transport the chimeric polypeptide across the endoplasmic reticulum. The secretory protein is then transported through the Golgi apparatus, into secretory vesicles and into the extracellular space or, preferably, the external environment. Signal peptides which can be utilized according to the invention include pre-pro peptides which contain a proteolytic enzyme recognition

- 18

site. Other signal peptides with similar properties to those described herein are known to those skilled in the art, or can be readily ascertained without undue experimentation.

5 The localization sequence can be a nuclear localization sequence, an endoplasmic reticulum localization sequence, a peroxisome localization sequence, a mitochondrial localization sequence, or a localized protein. Localization sequences can be targeting sequences which are described, for example, in "Protein Targeting", Chapter 35 of Stryer, L., *Biochemistry* (4th ed.), W.H. Freeman, 1995. The
10 localization sequence can also be a localized protein. Some important localization sequences include those targeting the nucleus (KKKRRK), mitochondrion (amino terminal MLRTSSLFTRRVQPSLFRNLRRLQST-), endoplasmic reticulum (KDEL at C-terminus, assuming a signal sequence present at N-terminus), peroxisome (SKF at C-terminus), synapses (S/TDV or fusion to GAP 43, kinesin and tau) prenylation or
15 insertion into plasma membrane (CaaX, CC, CXC, or CCXX at C-terminus), cytoplasmic side of plasma membrane (chimeric to SNAP-25), or the Golgi apparatus (chimeric to furin). The construction of expression vectors and the expression of genes in transfected cells involves the use of molecular cloning techniques also well known in the art. Sambrook *et al.*, *Molecular Cloning -- A Laboratory Manual*, Cold
20 Spring Harbor Laboratory, Cold Spring Harbor, NY, (1989) and *Current Protocols in Molecular Biology*, F.M. Ausubel *et al.*, eds., (Current Protocols, a joint venture between Greene Publishing Associates, Inc. and John Wiley & Sons, Inc., most recent Supplement). These methods include *in vitro* recombinant DNA techniques, synthetic techniques and *in vivo* recombination/genetic recombination. (See, for
25 example, the techniques described in Maniatis, *et al.*, *Molecular Cloning A Laboratory Manual*, Cold Spring Harbor Laboratory, N.Y., 1989).

Further, expression of the chimeric protein sensor of the invention can be targeted in a tissue specific manner, wherein the promoter is tissue specific. Examples of cells which can be targeted include but are not limited to a neural cell, an
30 endocrine cell, a glial cell, a secretory cell, an immune cell, a muscle cell, an epithelial cell, a liver cell, and an exocrine cell. Promoters or expression control

- 19

sequences can also target expression to a developmental stage or to a location within a cell, as discussed above. Such locations include the plasma membrane, the nuclear membrane, the Golgi apparatus, the endoplasmic reticulum, mitochondria, and
5 lysosome. Specific regions of a cell that can be targeted include the apical surface, the basolateral surface, the dendrites, a presynaptic region, a postsynaptic region, and the axons.

Depending on the vector utilized, any of a number of suitable transcription and translation elements, including constitutive and inducible promoters, transcription
10 enhancer elements, transcription terminators, *etc.* may be used in the expression vector (see, *e.g.*, Bitter, *et al.*, Methods in Enzymology 153:516-544, 1987). These elements are well known to one of skill in the art.

In bacterial systems a number of expression vectors may be advantageously selected depending upon the intended use. For example, when large
15 quantities of a protein of the invention is desired, vectors which direct the expression of high levels of chimeric protein products that are readily purified may be desirable. Those which are engineered to contain a cleavage site to aid in protein recovery are preferred.

In yeast, a number of vectors containing constitutive or inducible
20 promoters may be used. For a review see, Current Protocols in Molecular Biology, Vol. 2, Ed. Ausubel, *et al.*, Greene Publish. Assoc. & Wiley Interscience, Ch. 13, 1988; Grant, *et al.*, Expression and Secretion Vectors for Yeast, in Methods in Enzymology, Eds. Wu & Grossman, 31987, Acad. Press, N.Y., Vol. 153, pp.516-544, 1987; Glover, DNA Cloning, Vol. II, IRL Press, Wash., D.C., Ch. 3,
25 1986; and Bitter, Heterologous Gene Expression in Yeast, Methods in Enzymology, Eds. Berger & Kimmel, Acad. Press, N.Y., Vol. 152, pp. 673-684, 1987; and The Molecular Biology of the Yeast *Saccharomyces*, Eds. Strathern *et al.*, Cold Spring Harbor Press, Vols. I and II, 1982. A constitutive yeast promoter such as ADH or LEU2 or an inducible promoter such as GAL may be used (Cloning in Yeast, Ch. 3,

- 20

R. Rothstein In: DNA Cloning Vol.11, A Practical Approach, Ed. DM Glover, IRL Press, Wash., D.C., 1986). Alternatively, vectors may be used which promote integration of foreign DNA sequences into the yeast chromosome.

5 An alternative expression system which could be used to express the proteins of the invention is an insect system. In one such system, *Autographa californica* nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes. The virus grows in *Spodoptera frugiperda* cells. The sequence encoding a protein of the invention may be cloned into non-essential regions (for example, the
10 polyhedrin gene) of the virus and placed under control of an AcNPV promoter (for example the polyhedrin promoter). Successful insertion of the sequences coding for a protein of the invention will result in inactivation of the polyhedrin gene and production of non-occluded recombinant virus (*i.e.*, virus lacking the proteinaceous coat coded for by the polyhedrin gene). These recombinant viruses are then used to
15 infect *Spodoptera frugiperda* cells in which the inserted gene is expressed, see Smith, *et al.*, *J. Virol.* 46:584, 1983; Smith, U.S. Patent No. 4,215,051.

By "transformation" is meant a permanent genetic change induced in a cell following incorporation of new DNA (*i.e.* DNA exogenous to the cell). Where the cell is a mammalian cell, the permanent genetic change is generally achieved by
20 introduction of the DNA into the genome of the cell.

By "transformed cell" is meant a cell into which (or into an ancestor of which has been introduced), by means of recombinant DNA techniques, a DNA molecule encoding a chimeric protein consisting of an optically active polypeptide operatively fused to a responsive polypeptide, or fragment thereof, which normally
25 has two or more conformational shapes, and which undergoes a conformational change during a cell signaling or cellular event.

Transformation of a host cell with recombinant DNA may be carried out by conventional techniques as are well known to those skilled in the art. Where the host is prokaryotic, such as *E. coli*, competent cells which are capable of DNA uptake
30 can be prepared from cells harvested after exponential growth phase and subsequently treated by the CaCl_2 method by procedures well known in the art. Alternatively,

- 21

MgCl₂ or RbCl can be used. Transformation can also be performed after forming a protoplast of the host cell or by electroporation.

When the host is a eukaryote, such methods of transfection of DNA as
5 calcium phosphate co-precipitates, conventional mechanical procedures such as microinjection, electroporation, insertion of a plasmid encased in liposomes, or virus vectors may be used. Eukaryotic cells can also be cotransfected with DNA sequences encoding the chimeric polypeptide of the invention, and a second foreign DNA molecule encoding a selectable phenotype, such as the herpes simplex thymidine
10 kinase gene. Another method is to use a eukaryotic viral vector, such as simian virus 40 (SV40) adenovirus, vaccinia virus, or bovine papilloma virus, to transiently infect or transform eukaryotic cells and express the protein. (*Eukaryotic Viral Vectors*, Cold Spring Harbor Laboratory, Gluzman ed., 1982). Preferably, a eukaryotic host is utilized as the host cell as described herein. Methods of stable transfer, meaning that
15 the foreign DNA is continuously maintained in the host, are known in the art.

Eukaryotic systems, and preferably mammalian expression systems, allow for proper post-translational modifications of expressed mammalian proteins to occur. Eukaryotic cells which possess the cellular machinery for proper processing of the primary transcript, glycosylation, phosphorylation, and, secretion of the gene product
20 should be used as host cells for the expression of fluorescent indicator. Such host cell lines may include but are not limited to CHO, VERO, BHK, HeLa, COS, MDCK, Jurkat, HEK-293, and WI38.

Mammalian cell systems which utilize recombinant viruses or viral elements to direct expression may be engineered. For example, when using
25 adenovirus expression vectors, the nucleic acid sequences encoding a chimeric protein of the invention may be ligated to an adenovirus transcription/translation control complex, *e.g.*, the late promoter and tripartite leader sequence. This chimeric gene may then be inserted in the adenovirus genome by *in vitro* or *in vivo* recombination. Insertion in a non-essential region of the viral genome (*e.g.*, region
30 E1 or E3) will result in a recombinant virus that is viable and capable of expressing the fluorescent indicator in infected hosts (*e.g.*, see Logan & Shenk, *Proc. Natl. Acad.*

- 22

Sci. USA, 81: 3655-3659, 1984). Alternatively, the vaccinia virus 7.5K promoter may be used. (e.g., see, Mackett, *et al.*, *Proc. Natl. Acad. Sci. USA* 79: 7415-7419, 1982; Mackett, *et al.*, *J. Virol.* 49: 857-864, 1984; Panicali, *et al.*, *Proc. Natl. Acad. Sci. USA* 79: 4927-4931, 1982). Of particular interest are vectors based on bovine papilloma virus which have the ability to replicate as extrachromosomal elements (Sarver, *et al.*, *Mol. Cell. Biol.* 1: 486, 1981). Shortly after entry of this DNA into mouse cells, the plasmid replicates to about 100 to 200 copies per cell. Transcription of the inserted cDNA does not require integration of the plasmid into the host's chromosome, thereby yielding a high level of expression. These vectors can be used for stable expression by including a selectable marker in the plasmid, such as the *neo* gene. Alternatively, the retroviral genome can be modified for use as a vector capable of introducing and directing the expression of the fluorescent indicator gene in host cells (Cone & Mulligan, *Proc. Natl. Acad. Sci. USA*, 81:6349-6353, 1984). High level expression may also be achieved using inducible promoters, including, but not limited to, the metallothionine IIA promoter and heat shock promoters.

For long-term, high-yield production of recombinant proteins, stable expression is preferred. Rather than using expression vectors which contain viral origins of replication, host cells can be transformed with the cDNA encoding a chimeric protein of the invention controlled by appropriate expression control elements (e.g., promoter, enhancer, sequences, transcription terminators, polyadenylation sites, *etc.*), and a selectable marker. The selectable marker in the recombinant plasmid confers resistance to the selection and allows cells to stably integrate the plasmid into their chromosomes and grow to form foci which in turn can be cloned and expanded into cell lines. For example, following the introduction of foreign DNA, engineered cells may be allowed to grow for 1-2 days in an enriched media, and then are switched to a selective media. A number of selection systems may be used, including but not limited to the herpes simplex virus thymidine kinase (Wigler, *et al.*, *Cell*, 11: 223, 1977), hypoxanthine-guanine phosphoribosyltransferase (Szybalska & Szybalski, *Proc. Natl. Acad. Sci. USA*, 48:2026, 1962), and adenine phosphoribosyltransferase (Lowy, *et al.*, *Cell*, 22: 817, 1980) genes can be employed

- 23

in tk^r, hgp^rt^r or apr^rt^r cells respectively. Also, antimetabolite resistance can be used as the basis of selection for dhfr, which confers resistance to methotrexate (Wigler, *et al.*, *Proc. Natl. Acad. Sci. USA*, 77: 3567, 1980; O'Hare, *et al.*, *Proc. Natl. Acad. Sci. USA*, 8: 1527, 1981); gpt, which confers resistance to mycophenolic acid (Mulligan & Berg, *Proc. Natl. Acad. Sci. USA*, 78: 2072, 1981; neo, which confers resistance to the aminoglycoside G-418 (Colberre-Garapin, *et al.*, *J. Mol. Biol.*, 150:1, 1981); and hygro, which confers resistance to hygromycin (Santerre, *et al.*, *Gene*, 30: 147, 1984) genes. Recently, additional selectable genes have been described, namely trpB, which allows cells to utilize indole in place of tryptophan; hisD, which allows cells to utilize histinol in place of histidine (Hartman & Mulligan, *Proc. Natl. Acad. Sci. USA*, 85:8047, 1988); and ODC (ornithine decarboxylase) which confers resistance to the ornithine decarboxylase inhibitor, 2-(difluoromethyl)-DL-ornithine, DFMO (McConlogue L., In: *Current Communications in Molecular Biology*. Cold Spring Harbor Laboratory, ed., 1987).

A chimeric protein of the invention can be produced by expression of nucleic acid encoding the protein in prokaryotes. These include but are not limited to microorganisms such as bacteria transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors encoding a chimeric protein of the invention. A primary advantage of the optically active polypeptides of the invention is that they are prepared by normal protein biosynthesis, thus avoiding organic synthesis and the requirement for customized unnatural amino acid analogs. The constructs can be expressed in *E. coli* in large scale for *in vitro* assays. Purification from bacteria is simplified when the sequences include tags for one-step purification by nickel-chelate chromatography. The construct can also contain a tag to simplify isolation of the fluorescent indicator. For example, a polyhistidine tag of, *e.g.*, six histidine residues, can be incorporated at the amino terminal end of the fluorescent protein. The polyhistidine tag allows convenient isolation of the protein in a single step by nickel-chelate chromatography. Alternatively, the substrates can be expressed directly in a desired host cell for assays *in situ*.

- 24

Techniques for the isolation and purification of either microbially or eukaryotically expressed polypeptides of the invention may be by any conventional means such as, for example, preparative chromatographic separations and immuno-
5 logical separations such as those involving the use of monoclonal or polyclonal antibodies or antigen.

It should be understood that a nucleic acid sequence can also function as the responsive element in another embodiment of the invention. For example, a response may result from a DNA binding protein interaction with the chimeric
10 polypeptide of the invention when the chimeric polypeptide includes a DNA sequence having a DNA binding protein motif.

Screening Assays

The invention features a method for determining the presence of an activity in a sample, by contacting the sample with a chimeric protein of the
15 invention; exciting the chimeric protein; and measuring the amount of an optical property of the chimeric protein in the presence and absence of activity, such that a change in the optical property is indicative of activity in the sample. A series of standards, with known levels of activity, can be used for to generate a standard curve. The optical event, such as intensity of fluorescence, that occurs following exposure of
20 the sample to the chimeric protein is measured, and the amount of the optical property is then compared to the standard curve. A series of cellular standard, with known levels of activity, can be used to generate a standard curve, or to provide reference standards. The optical event, such as fluorescence, that occurs following exposure of the cell sample to the chimeric protein is measured, and the amount of the optical
25 property (*e.g.*, fluorescence) is then compared to the standards in order to generate a relative measure of activity.

In another embodiment, the invention features a method for determining if a cell exhibits an activity, which includes transfecting the cell with a nucleic acid encoding a chimeric protein of the invention; exciting the chimeric protein; and
30 measuring the amount of an optical property in the presence of the activity and in the

- 25

absence of the activity, such that a change in the optical property is indicative of activity. Typically, the optical property is calibrated against standard measurements to yield an absolute amount of protein activity.

5 It is understood that the cell containing a nucleic acid sequence encoding a chimeric protein of the invention can be used to co-transfect other genes of interest in order to determine the effect of the gene product of that gene on the cell or the responsive polypeptide of the chimeric protein. Therefore, a cell containing such a nucleic acid sequence is a composition provided by the present invention. For
10 example, a neural cell which expresses the chimeric protein exemplified in the Examples (FlaSh), can be used to co-transfect other genes of interest, such as serotonin, in order to determine the effect of serotonin on the cell as measured by activity of the Shaker ion channel. Other equivalent examples will be apparent or easily constructed by those of skill in the art without much need for further
15 experimentation.

 The invention can be used in screening assays to determine whether a compound (*e.g.*, a drug) alters the activity of a particular protein (*e.g.*, ligand binding to a receptor). In one embodiment, the assay is performed on a sample containing the chimeric protein *in vitro*. A sample containing a known amount of activity, such as
20 an enzymatic activity, is mixed with a chimeric protein substrate of the invention, with the co-factors required for activity, and with a test compound. The amount of the enzyme activity in the sample is then determined by measuring the amount of an optical property, such as a fluorescent property, at least a first and second time after contact between the sample, the chimeric protein substrate of the invention, and any
25 co-factors or components required to conduct the reaction, and the test compound. Then the amount of activity per mole of enzyme, for example, in the presence of the test compound is compared with the activity per mole of enzyme in the absence of the test compound. A difference indicates that the test compound alters the activity of the enzyme. In general a change in the optical parameter by any measurable amount
30 between activity in the presence of the test compound as compared with the activity in the absence of the test compound, is indicative of activity.

- 26

In another embodiment, the ability of a compound to alter the activity of a particular protein *in vivo* is determined. In an *in vivo* assay, cells transfected with a expression vector encoding a substrate of the invention are exposed to different
5 amounts of the test compound, and the effect on the optical parameter, such as fluorescence, in each cell can be determined. Typically, the difference is calibrated against standard measurements to yield an absolute amount of protein activity. This provides a method for screening for compounds which affect cellular events (*e.g.*, receptor-ligand binding, protein-protein interactions or protein kinase activation). In
10 a given cell type, any measurable change between activity in the presence of the test compound as compared with the activity in the absence of the test compound, is indicative of activity. In the present examples, a 0.1% change representing 1/50 of the signal was measurable, for example.

The materials of the invention are ideally suited for a kit for determining
15 the presence of an activity in a sample. Such a kit may contain a container containing a chimeric protein comprising an optically active polypeptide linked to a responsive polypeptide, or fragment thereof, which undergoes a change in response to the activity, wherein optical properties of the sensor are altered in response to the change in the responsive polypeptide, or fragment thereof. In another embodiment, a kit of
20 the invention contains an isolated nucleic acid sequence which encodes a chimeric protein comprising amino acid sequences encoding an optically active polypeptide linked to a responsive polypeptide, or responsive fragment thereof, which undergoes a conformational change in response to a cell signaling event, wherein an optical property of the sensor is altered in response to the conformational change in the
25 responsive polypeptide, or responsive fragment thereof. The nucleic acid sequence of the later kit may be contained in a host cell, preferably stably transfected. The cell could optionally be transiently transfected. Thus, the cell acts as an indicator kit in itself.

- 27

Transgenic Animals

In another embodiment, the present invention relates to transgenic animals that have cells that express an optically active polypeptide operatively fused to a responsive polypeptide, or fragment thereof, which normally has two or more conformational shapes, and which undergoes a conformational change during a cell signaling event. Transgenic animals expressing high levels of the tagged transgene may be obtained, for example, by over-expression of the transgene with an enhanced promoter and/or with high copy numbers of the transgene. The transgenic animal may be heterozygous or homozygous for an ablated or disrupted endogenous sensor gene. In specific embodiments, the invention features a transgenic mammal having a fluorescent-tagged channel protein, such as a GFP-potassium channel.

The "non-human animals" of the invention comprise any non-human animal having nucleic acid sequence which encodes a chimeric protein of the invention. Such non-human animals include vertebrates such as rodents, non-human primates, sheep, dog, cow, pig, amphibians, reptiles and fish. Preferred non-human animals are selected from the rodent family including rat and mouse, most preferably mouse. The "transgenic non-human animals" of the invention are produced by introducing "transgenes" into the germline of the non-human animal. Embryonal target cells at various developmental stages can be used to introduce transgenes. Different methods are used depending on the stage of development of the embryonal target cell. The zygote is the best target for micro-injection. In the mouse, the male pronucleus reaches the size of approximately 20 micrometers in diameter which allows reproducible injection of 1-2 pl of DNA solution. The use of zygotes as a target for gene transfer has a major advantage in that in most cases the injected DNA will be incorporated into the host gene before the first cleavage (Brinster *et al.*, *Proc. Natl. Acad. Sci. USA* 82:4438-4442, 1985). As a consequence, all cells of the transgenic non-human animal will carry the incorporated transgene. This will in general also be reflected in the efficient transmission of the transgene to offspring of the founder since 50%

- 28

of the germ cells will harbor the transgene. Microinjection of zygotes is the preferred method for incorporating transgenes in practicing the invention.

The term "transgenic" is used to describe an animal which includes
5 exogenous genetic material within all of its cells. A "transgenic" animal can be produced by cross-breeding two chimeric animals which include exogenous genetic material within cells used in reproduction. Twenty-five percent of the resulting offspring will be transgenic *i.e.*, animals which include the exogenous genetic material within all of their cells in both alleles. 50% of the resulting animals will
10 include the exogenous genetic material within one allele and 25% will include no exogenous genetic material.

Viral infection can also be used to introduce transgene into a non-human animal (e.g., retroviral, adenoviral or any other RNA or DNA viral vectors). The developing non-human embryo can be cultured *in vitro* to the blastocyst stage. During
15 this time, the blastomeres can be targets for retro viral infection (Jaenich, R., *Proc. Natl. Acad. Sci USA* 73:1260-1264, 1976). Efficient infection of the blastomeres is obtained by enzymatic treatment to remove the zona pellucida (Hogan, *et al.* (1986) in *Manipulating the Mouse Embryo*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.). The viral vector system used to introduce the transgene is
20 typically a replication-defective retrovirus carrying the transgene (Jahner, *et al.*, *Proc. Natl. Acad. Sci. USA* 82:6927-6931, 1985; Van der Putten, *et al.*, *Proc. Natl. Acad. Sci USA* 82:6148-6152, 1985). Transfection is easily and efficiently obtained by culturing the blastomeres on a monolayer of virus-producing cells (Van der Putten, *supra*; Stewart, *et al.*, *EMBO J.* 6:383-388, 1987). Alternatively, infection can be
25 performed at a later stage. Virus or virus-producing cells can be injected into the blastocoele (D. Jahner *et al.*, *Nature* 298:623-628, 1982). Most of the founders will be mosaic for the transgene since incorporation occurs only in a subset of the cells which formed the transgenic nonhuman animal. Further, the founder may contain various retro viral insertions of the transgene at different positions in the genome which

- 29

generally will segregate in the offspring. In addition, it is also possible to introduce transgenes into the germ line, albeit with low efficiency, by intrauterine retro viral infection of the midgestation embryo (D. Jahner *et al.*, *supra*).

5 A third type of target cell for transgene introduction is the embryonal stem cell (ES). ES cells are obtained from pre-implantation embryos cultured *in vitro* and fused with embryos (M. J. Evans *et al.* *Nature* 292:154-156, 1981; M.O. Bradley *et al.*, *Nature* 309: 255-258, 1984; Gossler, *et al.*, *Proc. Natl. Acad. Sci USA* 83: 9065-9069, 1986; and Robertson *et al.*, *Nature* 322:445-448, 1986). Transgenes can be effi-
10 ciently introduced into the ES cells by DNA transfection or by retro virus-mediated transduction. Such transformed ES cells can thereafter be combined with blastocysts from a nonhuman animal. The ES cells thereafter colonize the embryo and contribute to the germ line of the resulting chimeric animal. (For review see Jaenisch, R., *Science* 240: 1468-1474, 1988).

15 "Transformed" means a cell into which (or into an ancestor of which) has been introduced, by means of recombinant nucleic acid techniques, a heterologous nucleic acid molecule. "Heterologous" refers to a nucleic acid sequence that either originates from another species or is modified from either its original form or the form primarily expressed in the cell.

20 "Transgene" means any piece of DNA which is inserted by artifice into a cell, and becomes part of the genome of the organism (*i.e.*, either stably integrated or as a stable extrachromosomal element) which develops from that cell. Such a transgene may include a gene which is partly or entirely heterologous (*i.e.*, foreign) to the transgenic organism, or may represent a gene homologous to an endogenous gene
25 of the organism. Included within this definition is a transgene created by the providing of an RNA sequence which is transcribed into DNA and then incorporated into the genome. The transgenes of the invention include DNA sequences which encode the chimeric proteins of the invention which may be expressed in a transgenic non-human animal. The term "transgenic" as used herein additionally includes any
30 organism whose genome has been altered by *in vitro* manipulation of the early embryo or fertilized egg or by any transgenic technology to induce a specific gene

- 30

knockout. The term "gene knockout" as used herein, refers to the targeted disruption of a gene *in vivo* with complete loss of function that has been achieved by any transgenic technology familiar to those in the art. In one embodiment, transgenic
5 animals having gene knockouts are those in which the target gene has been rendered nonfunctional by an insertion targeted to the gene to be rendered non-functional by homologous recombination. As used herein, the term "transgenic" includes any transgenic technology familiar to those in the art which can produce an organism carrying an introduced transgene or one in which an endogenous gene has been
10 rendered non-functional or "knocked out."

Examples

Example 1 - Chimeric constructs of the Shaker potassium channel and GFP

ShH4 (GenBank X78908; Kamb *et al.*, *Neuron* 1(5):421, 1988) had been cloned in pBluescript (Stratagene), and site directed mutagenesis was used to engineer
15 the point mutation was engineered into the pore region of the channel, called W434F. W434F prevents ion conduction, but preserves the channel's gating rearrangements in response to voltage changes (Perozo *et al.*, 1993). The core of the Shaker channel, including the N-terminal assembly domain and the transmembrane segments, is highly conserved (Stuhmer *et al.*, 1989; Drewe *et al.*, 1992; Li *et al.*, 1992; Shen *et al.*,
20 1993), and likely to be intolerant to large insertions. Therefore, GFP was fused in-frame at a site just after the sixth transmembrane segment (S6, see Fig. 1A).

As the crystal structure of GFP indicates that its C-terminus is disordered from amino acid 330-238 (Ormo *et al.*, 1996; Yang *et al.*, 1996), and several amino acids can be removed without disrupting GP fluorescence (Dopf and Horigan, 1996),
25 amino acids 233-238 were deleted in the construct. Thus GFPΔC was amplified from the plasmid TU#65 (Chalfie, M., *et al.* (1994) *Science*, 263:802-805) using the primer sequence

5'-CCACTAGTAAAGGAGAAGAACTTTTC-3' (SEQ ID NO:1) and

5'-GGACTAGTGCCATGTGTAATCCCAGCAGCTGT-3' (SEQ ID NO:2). These
30 primers amplify amino acids 2-233 of GFP and add SpeI restriction sites in-frame to both ends.

- 31

GFP Δ C was inserted into ShH434F at the SpeI restriction site using standard techniques and the orientation of the insert was verified by digesting with NcoI, which cuts asymmetrically in GFP Δ C and ShH4. A Hpa I digest was used to
5 verify that only a single copy of GFPW Δ C was inserted into ShH4W434F. Thus, the structured, fluorescent core of GFP was directly linked to the movable parts of the channel (see Fig. 1A). This construct was called Shaker-W434GFP Δ C@S6, or "FlaSh." The predicted membrane orientation of FlaSh is shown in Fig. 1B.

Example 2 - *In vivo* Parameters and Fluorescence of FlaSh

10 FlaSh cDNA was transcribed using Megascript T7 (Ambion, Austin, TX) with a 4:1 methyl CAP to rGTP ratio, and the precipitated cRNA was resuspended in Ultrapure water (Specialty Media, Labelle, NJ) for injection. *Xenopus* oocytes were injected, using standard methods (Isacoff, E.Y., et al. (1990) *Nature*, 345:530-534) with cRNA transcribed from FlaSh.

15 Two-electrode voltage clamping was performed with a Dagan CA-1 amplifier (Dagan Corporation, Minneapolis, MN). External solution was NaMES (110 mM NaMES, 2 mM Ca(MES)₂, 10 mM Hepes, pH 7.5). Capacitance compensation was performed from a holding potential of +60mV. An HC120-05 photomultiplier (Hamamatsu, Bridgewater, NJ) was used for fluorescence
20 measurements, on a Nikon TMD inverted microscope. Data was sampled at 4kHz and fluorescence signals were low-pass filtered at 1kHz with an 8-pole Bessel filter (Frequency Devices, Haverhill, MA). Data was acquired onto a Digidata 1200 A/D interface (Axon Instruments, Foster City, CA). Data Acquisition and analysis were done with Axon Instruments Pclamp 6. Illumination was with a 100W Hg Arc lamp.
25 Exciting and emitted light were filtered through an HQ-GFP filter (Chroma Technology, Brattleboro, VT), with the following bandpass: ex: 425-475 nm, di: 480nm long-pass, em: 485-535nm.

Charge-voltage relations were constructed from the integrated "off" gating currents, evoked by repolarizations to -80 mV, after depolarizations that were long
30 enough for the "on" gating current to decay to completion. Fluorescence-voltage

- 32

relations were constructed from the amplitudes of the “on” fluorescence change from steps long enough to reach steady-state. Fluorescence traces in Figure 4A-E were digitally RC filtered at 300Hz. Linear reconstructions in Figure 4F&G were

5 performed with Matlab software (MathWorks).

Confocal images were acquired on a Nikon PCM-2000 microscope using the 488nm line of an Argon laser. Images were analyzed using the public domain NIH Image program (developed at the U.S. National Institutes of Health). Oocytes injected with W434GFPΔC@56 showed green membrane fluorescence (see Fig. 1C),
10 indicating that GFP was appropriately targeted.

As expected the W434F mutation abolished ionic current through the sensor. Voltage steps from a holding potential of -80 mV evoked only “on” and “off” gating currents (Fig. 2A). A maximum fluorescence decrease of $5.1 \pm 0.7\%$ ($n=7$) was observed in response to steps that moved all of the gating charge. Small
15 depolarizing voltage steps, which evoked only the gating charge component that was minor and fast, produced no fluorescence change. The relation of the steady-state gating charge to voltage was sigmoidal, and correlated closely with the steady-state gating charge to voltage relation (Fig. 2B). Thus, in FlaSh, the fluorescence emission of GFP is coupled to the voltage dependent rearrangements of the Shaker channel.

20 The FlaSh protein was very stable, as judged by gating a current and fluorescence measurements. Moreover, expression did not decline over a period of two weeks in *Xenopus* oocytes. No bleaching was visible after over five minutes of measurement with nearly continuous broad-band (425-475) excitation. In addition, FlaSh continued to respond to voltage when the temperature was increased from 22°C
25 to 37°C. The rates of both the onset and recovery of the fluorescence change were increased by 2.0 ± 0.3 ($n=3$) fold at the higher temperature.

Although the fluorescence of FlaSh follows the voltage dependence of Shaker activation, the kinetics of the “on” and “off” fluorescence changes (F_{on} and F_{off}) were slower than the movement of the gating charge (Q_{on} and Q_{off}) (see Fig 4). At
30 steps to 0mV, Q_{on} was approximately 30-fold faster ($p<0.0001$) than F_{on} ($\tau_{(Qon)} = 2.8 \pm 0.4$ ms, $\tau_{(Fon)} = 85 \pm 10$ ms, $n=5$). The kinetics of the fluorescence change indicate

- 33

that rearrangement in the voltage sensor of Shaker may trigger (but not cause directly) the change in GFP fluorescence.

The fluorescence response of FlaSh cannot be a direct consequence of N-type inactivation because F_{on} and F_{off} were slower than the onset and recovery of N-type inactivation. As shown earlier (Bezanilla et al., 1991), the onset of gating charge immobilization, and thus N-type inactivation, closely followed Q_{on} (Figure 3, I_g), which was more than an order of magnitude faster than F_{on} . Moreover, the immobilized Q_{off} at -80mV, following large depolarizations, returned approximately
10 twice as fast ($p < .001$) as F_{off} ($\tau_{(Q_{off})} = 72 \pm 7\text{ms}$, $\tau_{(F_{off})} = 160 \pm 12\text{ms}$, $n=7$).

The delay in the fluorescence change may arise from a time-dependent event in GFP, or a slow rearrangement in Shaker. The fluorescence change lacks intrinsic voltage sensitivity, whatever its mechanism, since the time-constants of both F_{on} and F_{off} saturate at voltages outside of the voltage range of activation (Figure 2C).

15 To determine whether FlaSh could respond to short-lasting electrical activity, we explored its fluorescence kinetics in response to brief voltage pulses. These voltage transients moved a fraction of the total gating charge, and steps of 3ms and longer evoked long, stereotypical fluorescent responses (Figure 3). While the magnitude of the fluorescence change was related to the duration of the step, its
20 kinetics of onset and recovery were constant. The entire collection of fluorescent responses was well-fit by a double-exponential with time constants of 23ms for F_{on} and 105ms for F_{off} . These kinetics are, respectively, 4-fold, and 1.5-fold faster than those of the fluorescence changes evoked by long steps.

This stereotyped fluorescence response was clearly visible in single-sweep
25 recordings (Figure 4). Subsequent events that occurred during the time-course of the fluorescence change summated with the original response. The unitary responses were visible in the summated response when the trains of electrical events were at frequencies of 20Hz or less. Trains at 100Hz produced a fused response in which the individual events could not be distinguished by eye.

30 For a short train of identical brief pulses, the integral of the fluorescence response was constant at frequencies of 20Hz and lower, but declined at higher

- 34

frequency. The decline occurred as the peak response approached the maximal fluorescence change, that is, as the sensor population became saturated. In the low frequency range, a linear filter model, with the kinetics of the unitary response based on the stereotypical shape of the FlaSh fluorescence change (Figure 3) accounted well for the shape of the fluorescence response to a pulse. Given the acceleration of FlaSh kinetics when temperature is increased from 22°C to 37°C, the maximal firing rate over which FlaSh will be linear may be twice the frequency cutoff of the cooler temperature.

10 Example 3 - Transgenic Mice Expressing Optical Sensors

Transgenic mice that can produce a chimeric protein encoding an optically active polypeptide linked to a responsive peptide are produced according to methods well known in the art. For example, young female mice are injected with hormones to induce superovulation, and are mated. The one-celled embryos are collected, and the pronuclei injected with a purified DNA solution containing the constructs which encode FlaSh. The injected eggs are cultured briefly, and re-implanted into pseudopregnant female mice. Genomic DNA is prepared from each progeny, and analyzed by PCR or Southern blot to determine the mouse's genotype. Mice who carry the transgene are subsequently mated in order to produce a line of mice.

20 Using these method mice are produced which contain transgenes encoding the optically active polypeptides responsive to cell signaling of the invention. In order to target the construct to specific cell types, transgenic mice are produced which carry the optically active polypeptides responsive to cell signaling genes encoding the under the control of specific promoters. Examples of such constructs are genes encoding FlaSh under the control of the neurofilament promoter, which specifically targets the expression of FlaSh to the neurons.

Other Embodiments

It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the

- 35

scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims. All patents and publications cited herein are hereby incorporated by reference.

- 36

What is claimed is:

1. A chimeric protein comprising an optically active polypeptide, or optically active fragment thereof, linked to a responsive polypeptide, or responsive
5 fragment thereof, which undergoes a change in response to a cell signaling event and wherein an optical property of the sensor is altered in response to the change in the responsive polypeptide, or responsive fragment thereof.
2. The chimeric protein of claim 1, wherein the optically active polypeptide is a protein that fluoresces in response to stimulation with light.
10
3. The chimeric protein of claim 1, wherein the optically active polypeptide is green fluorescent protein (GFP).
4. The chimeric protein of claim 3, wherein the GFP is a C-terminal deletion mutant of GFP.
- 15 5. The chimeric protein of claim 1, wherein the responsive polypeptide is a G-protein.
6. The chimeric protein of claim 1, wherein the change is a shift from a α -helix to a β -sheet.
- 20 7. The chimeric protein of claim 1 wherein the change is a shift from a β -sheet to a α -helix.
8. The chimeric protein of claim 1, wherein the responsive polypeptide is a channel protein.

- 37

9. The chimeric protein of claim 8, wherein the channel is a voltage-gated ion channel.

10. The chimeric protein of claim 8, wherein the channel is activated
5 by an intracellular or extracellular ligand.

11. The chimeric protein of claim 8, wherein the channel is selected from a sodium channel, a potassium channel, a calcium channel, a chloride channel, and a G-protein-sensitive channel.

12. The chimeric protein of claim 1, wherein the responsive
10 polypeptide is a receptor.

13. The chimeric protein of claim 12, wherein the receptor is a growth factor receptor.

14. The chimeric protein of claim 12, wherein the receptor is a neurotransmitter receptor.

15 15. The chimeric protein of claim 12, wherein the receptor is selected from the group consisting of the insulin-like growth factor and human growth factor.

16. The chimeric protein of claim 12, wherein the receptor is a hormone receptor.

17. The chimeric protein of claim 16, wherein the hormone is selected
20 from the group consisting of insulin, somatostatin, glucagon, and growth hormone.

- 38

18. The chimeric protein of claim 16, wherein the hormone receptor is a steroid receptor.

19. The chimeric protein of claim 18, wherein the hormone is selected
5 from the group consisting of estrogen, progesterone, and testosterone.

20. The chimeric protein of claim 12, wherein the receptor is a cytokine receptor.

21. The chimeric protein of claim 20, wherein the cytokine receptor is selected from the group consisting of interleukin-2 (IL-2), transforming growth factor
10 β (TGF- β), transforming growth factor α (TGF- α), interferon- γ (IFN- γ), and granulocyte macrophage colony stimulating factor (GM-CSF).

22. The chimeric protein of claim 1, wherein the responsive polypeptide is an enzyme.

23. The chimeric protein of claim 22, wherein the enzyme is a protein
15 kinase.

24. The chimeric protein of claim 22, wherein the enzyme is a phosphatase.

25. An isolated nucleic acid sequence which encodes a chimeric protein comprising an optically active polypeptide linked to a responsive polypeptide,
20 or responsive fragment thereof, which undergoes a change in response to a cell signaling event, wherein an optical property of the sensor is altered in response to the change in the responsive polypeptide, or responsive fragment thereof.

- 39

26. The nucleic acid sequence of claim 25, wherein the optically active polypeptide is a protein that fluoresces in response to stimulation with light.

27. The nucleic acid sequence of claim 25, wherein the optically active
5 polypeptide is green fluorescent protein (GFP).

28. The nucleic acid sequence of claim 27, wherein the GFP is a C-terminal deletion mutant of GFP.

29. The nucleic acid sequence of claim 25, further comprising expression control sequences operatively linked to the chimeric protein.

10 30. The nucleic acid sequence of claim 29, wherein the expression control sequence is a promoter.

31. The nucleic acid sequence of claim 30, wherein the promoter is tissue or cell specific.

32. The nucleic acid sequence of claim 31, wherein cell is selected
15 from the group consisting of a neural cell, an endocrine cell, an epithelial cell, a glial cell, a secretory cell, an immune cell, a muscle cell, a liver cell, and an exocrine cell.

33. The nucleic acid molecule of claim 29, wherein expression is targeted to a location selected from the group consisting of the plasma membrane, the nuclear membrane, the Golgi apparatus, the endoplasmic reticulum, mitochondria and
20 a lysosome.

34. The nucleic acid sequence of claim 29, wherein the expression is targeted to a region selected from the group consisting of the apical surface, the

- 40

basolateral surface, the dendrites, a presynaptic region, a postsynaptic region, and the axons.

35. A vector containing the nucleic acid sequence of claim 25.
- 5 36. The vector of claim 35, wherein the vector is a viral vector.
37. A host cell containing the vector of claim 35.
38. A method for determining the presence of an activity in a sample, comprising:
- 10 contacting the sample with a chimeric protein comprising an optically active polypeptide linked to a responsive polypeptide, or fragment thereof, which undergoes a change in response to the activity, wherein an optical property of the sensor is altered in response to the change in the responsive polypeptide, or fragment thereof;
- 15 exciting the chimeric protein; and measuring the optical property in the presence of the activity and in the absence of the activity, wherein a difference in the optical property is indicative of activity.
39. The method of claim 38, wherein the sensor is a fluorescent protein.
- 20 40. The method of claim 38, wherein the fluorescent protein is green fluorescent protein.

- 41

41. The method of claim 38, wherein the optical property is a fluorescent property.

42. The method of claim 38, wherein the activity is an enzymatic activity.

43. The method of claim 38, wherein the activity is a receptor binding activity.

44. A method for determining whether a cell exhibits an activity, comprising:

10 transfecting the cell with a recombinant nucleic acid molecule comprising expression control sequences operatively linked to a nucleic acid sequence encoding a chimeric protein, wherein the chimeric protein comprises an optically active polypeptide linked to a responsive polypeptide which undergoes a change in response to a cell signaling event, wherein the optical properties of the sensor are altered in response to the change in the responsive polypeptide;

exciting the chimeric protein; and

measuring the optical property in the presence of the activity and in the absence of the activity, wherein a difference in the optical property is indicative of activity.

20 45. A method for determining whether a compound alters a cell signaling event, comprising the steps of:

contacting a sample containing a known amount of a cell signaling activity with the compound and a chimeric protein substrate comprising an optically active polypeptide linked to a responsive polypeptide, or responsive fragment thereof, which undergoes a change in response to the cell signaling event and wherein an optical property of the sensor is altered in response to the conformational change in

25

- 42

the responsive polypeptide, or responsive fragment thereof,

exciting the protein substrate;

measuring the amount of cell signaling activity in the sample as a
5 function of the quantity of change or rate of change of an optical property that differs
before and after the cell signaling event ; and

comparing the amount of activity in the sample with a standard
activity for the same amount of the cell signaling event, whereby a difference between
the amount of activity in the sample and the standard activity indicates that the
10 compound alters the cell signaling.

46. A non-human transgenic animal comprising a recombinant nucleic
acid sequence comprising expression control sequences operatively linked to a
nucleic acid sequence encoding a chimeric protein, wherein the chimeric protein
comprises an optically active polypeptide linked to a responsive polypeptide which
15 undergoes a change in response to a cell signaling event, wherein the optical
properties of the sensor are altered in response to the conformational change in the
responsive polypeptide.

47. A kit for determining the presence of an activity in a sample,
comprising:
20 a chimeric protein comprising an optically active polypeptide linked to a
responsive polypeptide, or fragment thereof, which undergoes a change in response to
the activity, wherein optical properties of the sensor are altered in response to the
change in the responsive polypeptide, or fragment thereof.

48. A kit for determining the presence of the activity in a sample,
25 comprising:
an isolated nucleic acid sequence which encodes a chimeric protein
comprising amino acid sequences encoding an optically active polypeptide linked to a

- 43

responsive polypeptide, or responsive fragment thereof, which undergoes a conformational change in response to a cell signaling event, wherein an optical property of the sensor is altered in response to the conformational change in the

5 responsive polypeptide, or responsive fragment thereof.

49. The kit of claim 48, wherein the nucleic acid sequence is expressed in a host cell.

50. A purified green fluorescent protein having an amino acid sequence of wild-type GFP with a C-terminal deletion of amino acid residues 233-

10 238.

51. An isolated nucleic acid sequence encoding the protein of claim

50.


52. A recombinant cell line containing the chimeric protein of claim 1.

53. The cell line of claim 52, wherein the responsive polypeptide is a

15 channel protein and wherein the optically active polypeptide is GFP.

54. The cell line of claim 53, wherein the channel protein is a voltage-gated ion channel and wherein the optically active polypeptide is a modified GFP.

Figure 1



2/4

Figure 2






Figure 3



4/4

FIGURE 4



INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/19453

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : Please See Extra Sheet.

US CL : Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/69.7, 69.4, 183, 194, 195, 252.3, 320.1; 530/350, 303, 308, 311, 399

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS (USPAT, EPOABS, JPOABS); STN (CAPLUS, BIOSIS)

search terms: green fluorescent protein, fusion, chimera?

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X — Y	US 5,491,084 A (CHALFIE et al) 13 February 1996, column 1; column 4, lines 3-23; column 6, lines 1-19, columns 11-12, claims.	1-3, 38, 44, 47 4-24, 39-43
X — Y	GIROTTI et al. TGN38-green fluorescent protein hybrid proteins expressed in stably transfected eukaryotic cells provide a tool for the real-time, in vivo study of membrane traffic pathways and suggest possible role for rat TGN38. Journal of Cell Science. December 1996, Vol. 109, pages 2915-2926, especially page 2915, summary; page 2916, second column; page 2910, Fig. 4; page 2922, Fig. 6; page 2923, Fig. 8.	1-3, 38, 44, 47 4-24, 39-43



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
B earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

06 JANUARY 1998

Date of mailing of the international search report

10 FEB 1998

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231
Facsimile No. (703) 305-3230

Authorized officer

ELIZABETH SLOBODYANSKY

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/19453

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X — Y	CAREY et al. Evidence Using a Green Fluorescent Protein-Glucocorticoid Receptor Chimera that the RAN/TC4 GTPase mediates an essential Function Independent of Nuclear Protein Import. The Journal of Cell Biolgy. June 1996, Vol.133, pages 985-996, especially page 985; page 986, 1st column; page 987, 1st column, Results; page 992, figure 5.	1-3, 5, 12, 16, 17, 38, 43, 44, 47 4, 6-11, 13-15, 18-24, 39-42
X — Y	HTUN et al. Visualization of glucocorticoid receptor translocation and intranuclear organization in living cells with a green fluorescent protein chimera. Proc Natl. Acad. Sci. USA. May 1996, Vol. 93, pages 4845-4850, especially page 4845, abstract; page 4848, Fig. 3.	1-3, 5, 12, 16, 17, 38, 43, 44, 47 4, 6-11, 13-15, 39-42
X — Y	DOPF et al. Deletion mapping of the Aequorea victoria green fluorescent protein. Gene. 01 July 1996, Vol. 173, pages 39-44, especially page 39, summary; page 41, Table II; page 43, Fig. 3.	1-4, 38, 44, 47, 50 5-24, 39-43
X — Y	VENERANDO et al. Mitochondrial alterations induced by aspirin in rat hepatocytes expressing mitochondrially targeted green fluorescent protein (mtGFP). FEBS Letters. March 1996, Vol. 382, pages 256-260, especially page 256, abstract; page 257, Fig. 1; page 258, Fig. 2; page 259, Fig. 3.	1-3, 38, 44, 47 4-24, 39-43

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/19453

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☒ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
1-24, 38-44, 47, 50
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/19453

A. CLASSIFICATION OF SUBJECT MATTER: IPC (6):

C12P 21/04; C12N 1/20, 9/00, 9/12, 9/14, 15/00; C07K 1/00; A61K 38/24, 38/26, 38/28, 38/31

A. CLASSIFICATION OF SUBJECT MATTER: US CL :

435/69.7, 69.4, 183, 194, 195, 252.3, 320.1; 530/350, 303, 308, 311, 399

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING This ISA found multiple inventions as follows:

Group I, claim(s) 1-7, 38-43, 47, 50, drawn to a chimeric protein comprising green fluorescent protein (GFP) and a responsive polypeptide, a method of use thereof, and the first product, a chimeric protein comprising GFP and G-protein.

Group II, claim(s) 8-11, drawn to the second product, the chimeric protein comprising GFP and a channel protein.

Group III, claim(s) 12-21, drawn to the third product, a chimeric protein comprising GFP and a receptor.

Group IV, claim(s) 22-24, drawn to the fourth product, a chimeric protein comprising GFP and an enzyme.

Group V, claim(s) 25-37, 48, 49, 51-54, drawn to a DNA encoding said chimeric protein, a vector containing it and a cell transformed with the same.

Group VI, claim (s) 44, drawn to a method for determining an activity in a cell following expression of a chimeric protein in said cell.

Group VII, claim(s) 45, drawn to a method for determining whether a compound alters a cell signalling event using a chimeric protein.

Group VIII, claim(s) 46, drawn to a transgenic animal.

The inventions listed as Groups I-VIII do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: the products of Groups I-IV are chimera of GFP with different proteins, none of them making a contribution over the art. A chimeric protein of Groups I-IV and a DNA of Group V are different compounds with different chemical structures, functions and utilities.

Compounds of Groups I-V are different from an animal of Group VIII.

Groups VI and VII are drawn to methods of use of different products such as a chimeric protein and a modulating compound.

PCT Rule 1.475(d) does not provide for multiple products or methods within a single application and therefore, unity of invention is lacking with regard to Groups I-VIII.

THIS PAGE BLANK (USPTO)